Thank you for your interest in pursuing a career with us at BenevolentAI, although we don’t have a live role for this position, we frequently hire InVitro Biology Scientists. By applying to our talent pool, we will alert you as soon as we start hiring for this position again.

We actively encourage applications at all levels from Junior through to Director/VP.

With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.

Other Jobs You May Be Interested In

The Role

The In Vitro Biology team is focused on assay development and screening to support novel target identification and validation and progression of drug discovery programmes. You would contribute to our technology-enabled drug discovery programmes, from hit identification through to pre-clinical. Working with bioinformaticians, AI scientists and drug discovery colleagues you would devise creative ways to reimagine the way medicines are discovered.

We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey.

About us

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey.